15 Nov 2019 by admin in UncategorizedComments resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
14 Nov 2019 by admin in UncategorizedComments NextCure Announces Pricing of Public Offering of Common Stock
12 Nov 2019 by admin in UncategorizedComments Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
12 Nov 2019 by admin in UncategorizedComments NextCure Announces Proposed Public Offering of Common Stock
09 Nov 2019 by admin in UncategorizedComments NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial
08 Nov 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
05 Nov 2019 by admin in UncategorizedComments Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 Nov 2019 by admin in UncategorizedComments resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
04 Nov 2019 by admin in UncategorizedComments NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
